latter; in Switzerland, for example, a general 80% reduction in organic micropollutants from 68 raw sewage, evaluated by selected compounds, is envisaged for roughly 100 STPs by a new 69 water protection act. 27,28 70 Both options above naturally involve massive costs. Therefore, in deciding whether a given 71 STP and/or hospital should be modified for the elimination of pharmaceuticals, it is essential 72 to identify which catchments have high loads or high concentrations of pharmaceuticals in the 73 receiving waters. In large geographical areas with multiple substances, such assessments can 74 be very laborious when based on field monitoring; and in such cases, modeling approaches 75 are more useful. 29, 30 The discharge of domestically used compounds has been successfully 76 modeled using catchment-scale water quality models, such as GREAT-ER, 31 LF2000-WQX, 32 77 or similar approaches. 29, 33 In these models, however, hospitals are not included as emission 78 sources. Recently, Al Aukidy et al. 8 proposed a framework for assessing the environmental 79 risk posed by pharmaceuticals derived from hospital wastewater. They proposed to use 80 pharmaceutical concentrations in hospital wastewater reported in various countries as 81 reference concentrations, and use total hospital bed numbers in catchments to estimate the 82 dilution of the hospital wastewater by domestic wastewater. In their study, the estimated risk 83 quotient had an uncertainty of 2-3 orders of magnitude, owing to the large variation in 84 pharmaceutical concentrations in hospital wastewater in the literature. This uncertainty 85 increases in the case of pharmaceuticals not used in every hospital but only in specific types 86 of hospital; here, the spatial distribution of such pharmaceuticals would differ from that of 87 hospital beds, a case not addressed by Al Aukidy et al. However, assessments based on actual 88 consumption of pharmaceuticals in the target area, with consideration of hospital types, would 89 greatly reduce such uncertainty. In Australia and Switzerland, audit data of pharmaceutical 90 consumption obtained from hospitals was used to successfully estimate the hospital-based 91 contribution to pharmaceutical loads in one or a few STPs. 5, 7, 9 For assessment across a large 92 5 number of catchments, however, a model using more easily-available data (e.g., number of 93 beds, hospital types) is more convenient in terms of data collection and modeling. In 94 Germany, the mass flow of ICM in the urban water cycle of Berlin was predicted by a model 95 comprising 12 STPs and hospitals, using estimated ICM consumption data. 34 Thus far, 96 however, there has been no study on the modeling of different classes of hospital-use 97 pharmaceuticals across a large number of catchments, with consideration of hospital type. 98
Here, we proposed and validated a model-based method using national consumption data to 99 efficiently predict the geographical distribution of a diverse range of pharmaceuticals 100 (including some specifically used in hospitals) in STP effluents and rivers, at high spatial 101 resolution, incorporating multiple types of hospitals as geo-referenced point sources, across 102 all of Switzerland. The model is based on a previously developed national substance flow 103 model, which predicted the respective amounts of micropollutants discharged by the general 104 population. 29 Our objectives were to (i) test and compare distinct scenarios with different 105 levels of model complexity (i.e., pharmaceuticals were geographically distributed according 106 to (a) population size served by respective STPs, (b) total number of hospital beds, (c) number 107 of beds at specific hospitals, or (d) number of medical treatments related to specific 108 pharmaceutical usage); (ii) test different cases for varying ratios of outpatients to total 109 patients; (iii) validate the model through field measurements; and (iv) evaluate the 110 applicability of the model in terms of spatial resolution, model complexity, data acquisition 111 demands, and predictive uncertainty. 112 113 2. EXPERIMENTAL SECTION 114
Model setup 115
As a basis, we used a substance flow model for Switzerland. 29 The model incorporates a total 116 of 742 STPs, covering more than 98% of the general population (7.31 million). The input data 117 6 are (i) national pharmaceutical consumption data, (ii) excretion rates of pharmaceuticals, (iii) 118 elimination rates in municipal STPs, (iv) location and population of the catchments, and (v) 119 dilution in the receiving waters. No elimination was assumed in the rivers, as the 120 environmental half-lives of many pharmaceuticals are on the same order of magnitude or 121 larger than the maximum residence time of Swiss rivers (1 d). The base flow conditions (Q 347 ) 122 were used to account for minimum dilution in the rivers. Geographically, the total national 123 pharmaceutical loads were allocated proportionally to the population size of the respective 124 STP catchments, which ranged from 30-390,000 (average 9900, median 2700). 125 7 that was subsequently discharged from hospitals was expressed as (total consumption × HF), 142 and that discharged from the general population as (total consumption × (1−HF)). 143
The hospital-allocated pharmaceutical consumption (i.g., total consumption × HF) was 144 distributed to the respective hospitals according to the scenarios described in Section 2.3. The 145 consumption by the general population (i.g. total consumption × (1−HF)) was distributed in 146 proportion to the respective catchment populations. The respective consumption by hospitals 147 and by the general population was assigned for each STP, and the resulting loads and 148 concentrations of pharmaceuticals in STP effluents and rivers were predicted, taking excretion 149 from the human body and elimination at STPs into account, as in the base model. 29 This 150 allocation of pharmaceutical consumption to STP catchments is illustrated in Figure S1 hospitals in Switzerland (427 hospitals, with 44,892 beds in total). In addition, for hospitals 157 with radiology and/or oncology departments, information on the respective facilities, as well 158 as the actual numbers of treatments related to CT, MRI and inpatient chemotherapies, was 159 acquired. Further details of the data acquisition are described in S1 (SI). The number of in-use 160 beds was determined based on the occupancy rate for each hospital (median 90%, Q1 84%, 161 Q3 98%), and used for subsequent modeling and analysis, including the characteristic hospital 162 bed density per 1000 population (hereafter, B 1000 ). 163
In Switzerland, hospitals and hospital beds are concentrated in the large cities ( Figures S2 and  164 S3a). In comparison, B 1000 provides a different picture ( Figure S3b Five distinct scenarios were developed for distributing pharmaceuticals ( Table 1) . Four of 171 these were the hospital scenarios, in which hospital-allocated pharmaceutical consumption 172 was distributed over the number of hospital beds or specific treatments. For contrast media 173 and cytostatics, hospitals equipped with CT or MRI facilities, and hospitals with oncology 174 departments, were distinguished in bed-specific and treatment-specific scenarios. 175 Furthermore, for each pharmaceutical, the effect of HF variation was evaluated for two cases; 176 in the average case (AC), HF ac was set according to a realistic average proportion of expected 177 inpatients; in the high case (HC), HF hc was set at the same value as HF dis or slightly lower, 178 conservatively assuming a higher proportion of inpatients than the average case. The domestic 179 scenario was evaluated in comparison with the hospital scenarios. In the domestic scenario, 180 all the pharmaceutical consumption was allocated to the general population (i.e., HF = 0), as 181 in the base model. For the base model, the maximum uncertainty in the predicted pharmaceutical load 185 discharged from each STP, through variation of the model parameters, was evaluated as 186 64%. 29 In rivers, the uncertainty of Q 347 added further uncertainty, ranging from 30-70%, to 187 the predicted concentrations, depending on the river size. These uncertainties naturally 188 applied to the hospital scenarios as well. In addition, the uncertainty of the hospital data per 189 se must be accounted for. Briefly, the uncertainty was small (< 10%) for basic hospital data, 190 pharmaceutical consumption, and HF dis . In comparison, large uncertainty was found for 191 9 treatment numbers of MRI and chemotherapy. In 49% of hospitals equipped with MRI 192 facilities, and 74% of hospitals with an oncology department, treatment numbers were not 193 available, and thus had to be estimated. The actual treatment numbers (where available) did 194 not show a good correlation with the bed numbers ( Figures S4b and S4c ). Therefore, for each 195 hospital type (e.g., supply hospitals, primary care hospitals), the median of the actual 196 treatment numbers (SI, Table S1) was used, in order to avoid extreme over-or 197 underestimation. In contrast, the actual CT treatment numbers highly correlated with the bed 198 numbers (Pearson, r = 0.92, P < 0.001; Figure S4a ). Therefore, in 54% of CT hospitals where 199 treatment numbers were not available, linear regression using the respective bed numbers was 200 employed, and thus the uncertainty was expected to be small. Further details on the 201 uncertainty regarding input data for the hospital scenarios are described in S3. 202 203 2.5 Pharmaceuticals 204
We modeled and measured 19 compounds, including 11 major pharmacological classes. list, we selected pharmaceuticals which were representative and poorly eliminated during 208 sewage treatment. We studied seven ICM used for CT (Table 2) , representing the 209 pharmacological class which showed the highest consumption and was mainly dispensed in 210 hospitals (HF dis = 0.58). The seven ICM were modeled altogether as 'iodine', which was the 211 sum of the iodine content of all the ICM. This was because the occurrence of ICM measured 212 in the STP effluents varied significantly among catchments ( Figure S5 ), seemingly owing to 213 varying hospital preferences. Gadolinium complexes are used for MRI as contrast media, and 214 are dispensed only in hospitals (HF dis = 1). Therefore, gadolinium (Gd) is most useful for 215 to be stable and non-reactive, and are quickly excreted from the human body, with a 1.3-2 h 217 half-life. 36, 37 In addition, they are not removed during conventional sewage treatment. 38 
218
Cyclophosphamide was selected as a model cytostatic, because it is used only for 219 chemotherapy and has a large HF dis (0.68). Sulfamethoxazole (HF dis = 0.17) was selected 220 because of its broad use as an antibiotic in general hospitals. In addition, we selected eight 221 more pharmaceuticals with relatively small HF dis (0.03-0.49). Benzotriazole, which is closely 222 related to domestic wastewater (i.e., HF dis = 0), was selected as a reference compound. 39 The 223 modeled compounds included four of the five originally proposed indicator compounds used 224 to evaluate the removal of micropollutants in advanced wastewater treatment as envisaged in 225 the new Swiss water protection act. 27,28 Excretion rates and elimination in STP were based on 226 averages from literature data. The parameters and scenarios for the ICM, gadolinium, 227 cyclophosphamide and sulfamethoxazole are shown in Table 2 ; and those for the remaining 228 compounds, in Table S2 . 229 230
Field sampling and laboratory analyses 231
Samples of 14 STP effluents and 7 river waters in Switzerland (Table S3; (Table S4) . The measured pharmaceutical mass flows were determined by multiplying the measured 254 concentrations by the actual discharge over the sampling period, for each STP and river 255 (Table S5 ). The agreement between the respective calculated and modeled average daily mass 256 flows was evaluated, following Ort et al., 29 using the predictive accuracy factor 257 (prediction/observation; hereafter, PAF), its median value (MPAF), its relative standard 258 deviation (RSD), and the R 2 from the linear regression forced through 0. 259
The benzotriazole mass flow predicted by the domestic scenario agreed well with the 260 measured mass flow, both in the STP effluents and the rivers ( Figure S6 ); and this showed 261 that the domestic scenario was valid for predicting compounds used domestically. 262
Throughout the paper, evaluations are mainly based on the results for ICM, gadolinium, 263 cyclophosphamide and sulfamethoxazole. The predicted mass flow and concentrations of 264 those four compounds in all the STP effluents and river waters, along with their relative 265 change, are shown in Table S6 . 266 Overall. Our results showed that the hospital scenarios predicted higher mass flows than the 271 domestic scenario only in a small number of catchments (Figures 1a, 2 , S7-S9). In 76% of all 272 catchments with 30-100,000 population and no hospital beds, the change relative to the 273 domestic scenario was simply (1-HF) for all the hospital scenarios, because the catchments 274 had no hospital-allocated pharmaceutical consumption (see Figure S1 for the expected 275 relative change depending on catchment characteristics). Among all the scenarios, the relative 276 change exceeded 1 in 8-15% of catchments (Tables S7 and S8) , where the number of hospital 277 beds or treatments per population were above the respective national average values (Table  278 S9). Large relative changes were found in a few percent of catchments, which were mostly 279 suburban or relatively remote, with 1000-10,000 population. These catchments differed 280 among scenarios and compounds, depending on the services provided by the hospitals. In 281 contrast, in catchments with more than 100,000 population, the predicted mass flows varied 282 less among scenarios and compounds, and the relative change mostly ranged from 1-3. This 283 indicated an abundance of hospitals of all types in these heavily populated catchments. 284
The all beds scenario had more catchments with large relative changes than the other 285 scenarios. This is because, in all beds, catchments containing any type of hospital are 286 assigned hospital-allocated pharmaceutical consumption. Therefore, a very large relative 287 change was found in catchments where the existence of hospitals of special types caused large 288 B 1000 (e.g., suburban catchments). In such catchments, the all beds scenario can overestimate 289 the mass flow of specific pharmaceuticals. For example, the relative change for ICM and 290 gadolinium in all beds was the largest (e.g., around 7 for ICM, AC) in the two small 291 catchments of Rheinau and Schinznach-Bad ( Figure 2 ), both of which have a population of 292 1300 and the highest B 1000 values (118 and 108, respectively). However, this result is 293 unrealistic, because the catchments only contain a psychiatric hospital (Rheinau), and a 294 rehabilitation hospital (Schinznach-Bad), neither of which has a radiology department; and 295 the field measurements confirmed the overestimation of contrast media in these catchments 296 (Section 3.2.1). 297
Contrast media. The contrast media included ICM (HF ac = 0.3, HF hc = 0.5) and gadolinium 298 (HF ac = 0.5, HF hc = 0.8). In the CT beds scenario, the largest relative changes, of 3.9 (AC) and 299 5.8 (HC), were found in STP Saignelegier (2100 population) and STP Zurzach (7500). 300
Gadolinium showed the largest relative change because it has the largest HF value. In the MRI 301 beds scenario, the largest relative changes (3.7-6.7 in AC, 5.3-10.1 in HC) were found in six 302 catchments, with varying population ranging from 2100-52,000. In the MRI treatments 303 scenario, the maximum relative change was even larger, at 22.4 (STP Saignelegier, HC); note, 304 however, that the treatment number in this catchment was estimated. 305
Other pharmaceuticals. Various HF values (HF ac = 0.01-0.1, HF hc = 0.03-0.49) were applied 306 to the remaining ten pharmaceuticals. Among the latter, ritonavir had the largest relative 307 change (e.g., 3.1 in all beds, AC, STP Rheinau). In the case of cyclophosphamide (HF ac = 308 0.05, HF hc = 0.34), the relative change reached 1.5 in the oncology beds and chemotherapy 309 scenarios for AC, and 3.8 in oncology beds for HC. Regarding sulfamethoxazole (HF ac = 0.03, 310 HF hc = 0.17), the relative change reached 1.7 (AC) and 4.5 (HC) in all beds, and 1.4 (AC) and 311 3.2 (HC) in general beds. 312
Comparison between bed-specific scenarios and treatment-specific scenarios. The 313
respective predictions by the bed-specific and treatment-specific scenarios did not differ much 314 for ICM ( Figure S10 ). In comparison, the difference was large for gadolinium (up to a factor 315 of 2) and cyclophosphamide (up to 4). This reflects the fact that bed and treatment numbers 316 did not correlate well in the case of MRI and chemotherapy ( Figures S4b and S4c ). However, 317 missing treatment numbers produced large uncertainties (Section 2.4); therefore, great care 318 should be taken in the case of treatment-specific scenarios in such catchments. 319 320
Rivers 321
Similarly to STP effluents, the relative changes were largest in catchments with 1000-10,000 322 upstream population (Figures 1b, S11 -S13). The largest relative changes in rivers (e.g., 3.9 323 for ICM in CT beds, AC) were similar to those in STP effluents. However, large relative 324 changes were found in fewer river waters than STP effluents (Tables S10 and S11); for 325 example, relative changes of greater than 3 for gadolinium in MRI beds (AC) were noted in 326 effluents of six STPs but in only three river waters. All the scenarios predicted very similarly 327 in rivers where the upstream population exceeded 10,000. As the loads of all the upstream 328 STPs were aggregated, the respective differences from the domestic scenario were averaged 329 out. 330 331 3.2 Model validation by measurement 332
Contrast media 333
As explained above, the all beds scenario was inappropriate for modeling ICM and 334 gadolinium (e.g., MPAF 3.0, RSD 469% for ICM, AC; Figure 3 , and Tables S12 and S13). 335
Especially in the STP catchments of Rheinau and Schinznach-Bad, the all beds scenario 336 considerably overestimated the contrast media (PAF 11-55), because the catchments did not 337 have CT or MRI facilities. In contrast, the facility-specific scenarios showed better agreement 338 with the measured values (e.g., PAF 1.2-3.6 in MRI beds, AC) in those catchments. 339
The domestic, CT beds and CT treatments scenarios somewhat overestimated ICM in the STP 340 effluents (MPAF 1.5-2.5, AC; Figure 3a ), although the magnitude of overestimation was not 341 markedly higher than the base model uncertainty. The observed overestimation may have 342 partly derived from the uncertainties of consumption numbers and/or the varying elimination 343 rates of ICM in the STPs. The reported elimination of ICM varied largely (e.g., 0-90% for 344 iopromide), possibly due to varying sludge age and/or degree of nitrification. 20,41-43 In our 345 model, an average elimination rate of 40% was assumed (Table 2) . Among the scenarios, 346 domestic had an MPAF closest to 1, with the largest R 2 value (Figure 3a in four of these catchments (PAF 0.13-0.37 in domestic against 0.55-2.4 in MRI beds). In the 364 remaining STP, Langnau (indicated in Figures 3, S14 and S15), the catchment's PAF was 365 better in domestic (0.88) than in MRI beds (4.0), and the ICM values were also predicted 366 better by the domestic scenario. In this catchment, CT and MRI facilities were only installed 367 two months before the sampling campaign, and therefore usage of contrast media was 368 probably still low, which may explain the overestimation by the hospital scenarios. 369
In three catchments where the treatment numbers were all actual numbers, the respective PAF 370 values for MRI treatments, AC (0.59, 0.75 and 0.81), were similar to those for MRI beds, AC 371 (0.79, 0.55 and 0.61). In five catchments where all the treatment numbers were estimated, 372 MRI treatments (AC) predicted well compared to the catchments with actual treatment 373 numbers, but showed greater variation (PAF 0.99-2.8, median 1.6). 374
More catchments exhibited over-or underestimation in HC than in AC, for both ICM and 375 gadolinium (Figures S14 and S15), which shows that the assumed HF hc was too large. 376
In rivers, the contrast media were predicted well by both bed-specific scenarios and 377 treatment-specific scenarios in AC (e.g., MPAF 1.8, RSD 32%, R 2 1.00 in CT beds; and 0.67, 378 38%, 1.00 in MRI beds; Figures S14 and S15) . 379 380
Other pharmaceuticals 381
The predictions for the other pharmaceuticals in AC did not differ much among scenarios, and 382 mostly agreed with measured loads (within a factor of 2), both in the STPs and rivers (Figures 383 S16-S19, Tables S12-S15). Interestingly, however, for cyclophosphamide, sulfamethoxazole, 384 carbamazepine and diclofenac, the all beds scenario generally predicted better than domestic 385 and general beds in the STP catchments where psychiatric and/or rehabilitation hospitals 386 accounted for more than half of the total hospital beds (e.g., in STP Rheinau, for 387 cyclophosphamide, PAF 0.93 in all beds, compared with < 0.46 in the other scenarios). This 388 suggests that the special types of hospital discharged these pharmaceuticals, unlike the 389 contrast media, at rates similar to general hospitals. Overall, these results suggest that 390 incorporating hospitals as point sources is important in catchments with high B 1000 , even for 391 compounds with small HF; and that great care should be taken when estimating 392 pharmaceutical discharges from small catchments with high B 1000 . 393 394 4. DISCUSSION 395
Parameters and scenarios 396
Our results showed that, in a large proportion (> 95%) of both STP effluents and rivers in 397
Switzerland, the predictions of the hospital scenarios did not differ much from those of the 398 domestic scenario (e.g., relative change < 1.5). In a few percent of catchments and rivers, 399 however, the difference from the domestic became larger, and the hospital scenarios showed 400 greater predictive accuracy. For example, in the all beds scenario, with HF = 0.3, the largest 401 relative change was 7.2, and the relative change exceeded 2 in 24 of the STP catchments, 402 serving 2.1% of the national population (158,000). The magnitude of the difference from 403 domestic values depended on B 1000 and HF (see also S5 and Figure S20 for theoretical 404 explanation). HF is the most critical model parameter in determining the allocation of 405 pharmaceuticals between hospitals and households; the other parameters, such as excretion 406 and elimination, have no effect on this allocation. The large impact of HF variation on the 407 model predictions was demonstrated by the two cases, AC and HC. With a large HF of 0.8, 408
the change relative to the domestic scenario could reach 22. Nevertheless, the agreement 409 between the modeled and measured loads was generally better when HF was set at half of 410 HF dis or less. This shows that a significant fraction of pharmaceuticals dispensed within 411 hospitals were discharged outside the hospitals, and that HF is therefore meaningful only if it 412 is reduced from HF dis by the appropriate portion of outpatients (see Section 2.1). It should 413 also be noted that, even for general pharmaceuticals with small HF, the relative change can be 414 large in catchments with high hospital bed density, where the hospital scenarios predict better 415 than the domestic scenario (see 3.2.2). The hospital bed density can vary widely (e.g., up to 21 416 times the national average in Switzerland; see S2), often owing to the presence of special 417 hospital types (e.g., psychiatric or rehabilitation hospitals). In this study, these special types of 418 hospital were, like general hospitals, found to be the sources of many general 419 pharmaceuticals, favoring the all beds scenario. On the other hand, in the case of 420 pharmaceuticals used for specific treatments (i.e., in this study, ICM and gadolinium), the all 421 beds scenario should not be applicable, and the relevant hospitals must be distinguished in 422 bed-specific or treatment-specific scenarios. For such pharmaceuticals, bed-specific scenarios 423 are typically more reliable than treatment-specific scenarios, because (as in the present study) 424 bed numbers and occupancy are far more easily accessed and have smaller uncertainties in 425 estimation than treatment numbers. In the cases where treatment numbers were available in 426 this study, however, the measured values agreed as well with the predictions of the 427 treatment-specific scenarios as they did with those of the bed-specific scenarios. 428
The data used for the hospital scenarios can change over time, although typically not rapidly 429 (e.g., 2% annual change in Switzerland; see S3). Thus, these data would need to be updated 430 regularly (e.g., every few years). In the case of pharmaceuticals used for specific treatments 431 (e.g., ICM, gadolinium), information such as the establishment or abolishment of 432 corresponding facilities must be updated; otherwise, the discharge from hospitals may be 433 significantly over-or underestimated. 434 435
Applicability 436
Through the comparison of different scenarios, our study revealed the relationship between 437 spatial resolution, model complexity and predictive accuracy. At low spatial resolution (e.g., 438 large river-catchments), the difference between scenarios was very small for all the 439 pharmaceuticals tested, as shown in the results of rivers with large upstream population. In 440 contrast, at high spatial resolution (e.g., STP catchment or small river-catchments), the 441 difference was larger, and the hospital scenarios showed good predictive accuracy (e.g., 442 within a factor of 2). In this case, the domestic scenario could produce discrepancies of up to 443 1 order of magnitude. 444 Therefore, at low spatial resolution, the domestic scenario is a simple and efficient model for 445 predicting the distribution of a diverse range of pharmaceuticals. Incorporating geo-referenced 446 STP and pharmaceutical consumption data, the domestic scenario is suitable for identifying 447 potential river catchments of concern in a large geographical area (e.g., at the national or 448 regional level). Our results suggest that other, population-based models for predicting the 449 discharge of domestic-use compounds (e.g., carbamazepine and diclofenac) 31-33 can also 450 accurately predict hospital-use pharmaceuticals on the scale of large catchments of rivers. 451
In contrast, the hospital scenarios can be used most effectively at high spatial resolution. 452
These scenarios additionally incorporate geo-referenced hospital data; information on hospital 453 type, bed number and bed occupancy; and HF. Therefore, the hospital scenarios are most 454 suitable for the detailed evaluation of smaller regions of interest (e.g., at the county or 455 prefectural level), or catchments of particular rivers, where the related data-collection efforts 456 are justified. Large relative changes (vs. the domestic scenario) were found mostly in 457 suburban STPs and small rivers with high catchment B 1000 . Nevertheless, large cities also 458 tended to have a relatively high B 1000 , and thus significant relative change (up to 3). Therefore, 459
the hospital scenarios are also useful for urban STPs and their adjacent receiving waters. 460
Through field measurement, we validated our scenarios in STP catchments of various sizes 461 (1300-52,000 population). In both the hospital scenarios and domestic scenario, the predictive 462 uncertainty was less than the uncertainty in the approach of Al Aukidy et al. 8 treatments are shown separately according to the ratio of the estimated treatment number (< 539 50% and ≥ 50%) to the total treatment number in each catchment (see Table S6 for the data). and MRI treatments are shown separately according to the ratio of the estimated treatment 545 number (< 50% and ≥ 50%) to the total treatment number in each catchment (Table S4) 
